ProShares Trust II
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
SCO$20.19+2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ProShares Ultra Euro
| March 31, 2024 (unaudited) | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Cash | $6,451,388 | $6,162,459 |
| Segregated cash balances with brokers for foreign currency forward contracts | 533,000 | 623,000 |
| Unrealized appreciation on foreign currency forward contracts | 965 | 308,424 |
| Interest receivable | 27,781 | 27,219 |
| Total assets | 7,013,134 | 7,121,102 |
| Liabilities and shareholders’ equity | ||
| Liabilities | ||
| Payable to Sponsor | 5,556 | 5,612 |
| Unrealized depreciation on foreign currency forward contracts | 203,530 | 1,475 |
| Total liabilities | 209,086 | 7,087 |
| Commitments and Contingencies (Note 2) | ||
| Shareholders’ equity | ||
| Shareholders’ equity | 6,804,048 | 7,114,015 |
| Total liabilities and shareholders’ equity | $7,013,134 | $7,121,102 |
| Shares outstanding | 600,000 | 600,000 |
| Net asset value per share | $11.34 | $11.86 |
| Market value per share (Note 2) | $11.32 | $11.84 |
^
| Settlement Date | Contract Amount in Local Currency | Contract Amount in U.S. Dollars | Unrealized Appreciation (Depreciation)/ Value | |
|---|---|---|---|---|
| Contracts to Purchase | ||||
| Euro with Goldman Sachs International | 04/05/24 | 5,678,921 | $6,127,948 | $(90,225) |
| Euro with UBS AG | 04/05/24 | 7,153,502 | 7,719,122 | (113,305) |
| Total Unrealized Depreciation | $(203,530) | |||
| Contracts to Sell | ||||
| Euro with UBS AG | 04/05/24 | (221,000) | $(238,475) | $965 |
| Total Unrealized Appreciation | $965 | |||
| ^ | The positions and counterparties herein are as of March 31, 2024. The Fund continually evaluates different counterparties for their transactions and counterparties are subject to change. New counterparties can be added at any time. |
|---|
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Investment Income | ||
| Interest | $78,486 | $97,237 |
| Expenses | ||
| Management fee | 15,935 | 24,246 |
| Total expenses | 15,935 | 24,246 |
| Net investment income (loss) | 62,551 | 72,991 |
| Realized and unrealized gain (loss) on investment activity | ||
| Net realized gain (loss) on | ||
| Foreign currency forward contracts | 144,574 | 280,279 |
| Net realized gain (loss) | 144,574 | 280,279 |
| Change in net unrealized appreciation (depreciation) on | ||
| Foreign currency forward contracts | (509,514) | (96,945) |
| Change in net unrealized appreciation (depreciation) | (509,514) | (96,945) |
| Net realized and unrealized gain (loss) | (364,940) | 183,334 |
| Net income (loss) | $(302,389) | $256,325 |
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Shareholders’ equity, beginning of period | $7,114,015 | $10,704,662 |
| Addition of 100,000 and 200,000 shares, respectively | 1,140,357 | 2,296,437 |
| Redemption of 100,000 and 400,000 shares, respectively | (1,147,935) | (4,640,991) |
| Net addition (redemption) of – and (200,000) shares, respectively | (7,578) | (2,344,554) |
| Net investment income (loss) | 62,551 | 72,991 |
| Net realized gain (loss) | 144,574 | 280,279 |
| Change in net unrealized appreciation (depreciation) | (509,514) | (96,945) |
| Net income (loss) | (302,389) | 256,325 |
| Shareholders’ equity, end of period | $6,804,048 | $8,616,433 |
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flow from operating activities | ||
| Net income (loss) | $(302,389) | $256,325 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Change in unrealized (appreciation) depreciation on investments | 509,514 | 96,945 |
| Decrease (Increase) in interest receivable | (562) | 9,474 |
| Increase (Decrease) in payable to Sponsor | (56) | (3,189) |
| Net cash provided by (used in) operating activities | 206,507 | 359,555 |
| Cash flow from financing activities | ||
| Proceeds from addition of shares | 1,140,357 | 2,296,437 |
| Payment on shares redeemed | (1,147,935) | (4,640,991) |
| Net cash provided by (used in) financing activities | (7,578) | (2,344,554) |
| Net increase (decrease) in cash | 198,929 | (1,984,999) |
| Cash, beginning of period | 6,785,459 | 10,259,418 |
| Cash, end of period | $6,984,388 | $8,274,419 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.